LCAR-B38M

LCAR-B38M · Nanjing Legend Biotech Co.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LCAR-B38M, covering 2023-06-12 to 2023-06-12. Get the full timeline:

Most recent: Clinical Trial Update: LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma [Phase 1, Phase 2]